1. Home
  2. MMA vs LNAI Comparison

MMA vs LNAI Comparison

Compare MMA & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MMA

Alta Global Group Limited

HOLD

Current Price

$0.75

Market Cap

11.8M

Sector

N/A

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.31

Market Cap

11.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MMA
LNAI
Founded
2013
N/A
Country
Australia
United States
Employees
N/A
29
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
11.9M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
MMA
LNAI
Price
$0.75
$0.31
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
411.0K
17.1M
Earning Date
05-20-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.35
$0.15
52 Week High
$2.00
$1.66

Technical Indicators

Market Signals
Indicator
MMA
LNAI
Relative Strength Index (RSI) 74.35 44.76
Support Level $0.35 $0.27
Resistance Level $1.42 $0.54
Average True Range (ATR) 0.06 0.06
MACD 0.04 -0.00
Stochastic Oscillator 92.90 17.58

Price Performance

Historical Comparison
MMA
LNAI

About MMA Alta Global Group Limited

MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: